Send to

Choose Destination
Vaccine. 2013 May 31;31(24):2667-72. doi: 10.1016/j.vaccine.2013.04.012. Epub 2013 Apr 16.

Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.

Author information

Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, United States.


Shigellosis is an important diarrheal disease, especially among children in the developing world. About 90 million infections with Shigella spp are estimated to appear each year. We previously demonstrated that the type III secretion apparatus (T3SA) proteins IpaB and IpaD are protective antigens when administered intranasally using the mouse lethal pulmonary model. To simplify vaccine administration, we tested the parenteral route for IpaB and IpaD with several adjuvants and compared the immune response and protective efficacy via the intranasal route. We found that the intramuscular administration generated a response consisting of similar levels of serum IgG, a lack of IgA response and higher IL-17 secretion. Therefore, while parenteral administration yielded a unique pattern of immune responses, it retained the ability to protect mice in a lethal pulmonary challenge against S. flexneri when both proteins were used. Our results show the feasibility of generating protective parenteral vaccines against Shigella spp.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center